Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Reaffirmed by Zacks Investment Research

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “hold” rating reissued by Zacks Investment Research in a note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Separately, HC Wainwright set a $36.00 price objective on shares of Y-mAbs Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.80.

Y-mAbs Therapeutics stock traded up $0.42 during mid-day trading on Friday, hitting $22.31. The stock had a trading volume of 136,448 shares, compared to its average volume of 139,480. The company has a market capitalization of $748.50 million and a P/E ratio of -14.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30. Y-mAbs Therapeutics has a one year low of $15.17 and a one year high of $31.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Analysts forecast that Y-mAbs Therapeutics will post -1.95 EPS for the current year.

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 6,000 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $20.61, for a total transaction of $123,660.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 270,000 shares of company stock valued at $6,888,700 in the last three months.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock valued at $122,000 after purchasing an additional 5,838 shares during the last quarter. Vanguard Group Inc purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $2,260,000. American International Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $93,000. Strs Ohio purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $38,000. Finally, Barclays PLC purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $210,000. 24.80% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.